Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.84 |
| ▸ | DRD3 | P35462 | 6/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.84 |
| ▸ | DRD2 | P14416 | 5/20 | 0.84 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.84 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.84 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.84 |
| ▸ | DRD1 | P21728 | 4/20 | 0.84 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.84 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.84 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.84 |
| ▸ | HTR2A | P28223 | 4/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clocinizine SCHEMBL2193158 | 1.00 | LMNA (0.84) | LMNACYP2D6DRD3HIF1ACYP3A4 | |
| Clocinizine SCHEMBL4416376 | 0.99 | LMNA (0.82) | LMNACYP2D6DRD3HIF1ACYP3A4 | |
| Clocinizine SCHEMBL6659465 | 0.99 | LMNA (0.82) | LMNACYP2D6DRD3HIF1ACYP3A4 | |
| Cinnarizine SCHEMBL44958 | 0.92 | LMNA (1.00) | LMNACYP2D6DRD3HIF1ACYP3A4 | |
| Cinnarizine SCHEMBL1815115 | 0.92 | LMNA (1.00) | LMNACYP2D6DRD3HIF1ACYP3A4 | |
| Cinnarizine SCHEMBL44957 | 0.92 | LMNA (1.00) | LMNACYP2D6DRD3HIF1ACYP3A4 | |
| Cinnarizine SCHEMBL16225873 | 0.92 | LMNA (1.00) | LMNACYP2D6DRD3HIF1ACYP3A4 | |
| Cinnarizine SCHEMBL10936878 | 0.90 | LMNA (0.97) | LMNACYP2D6DRD3HIF1ACYP3A4 | |
| Cinnarizine SCHEMBL3731524 | 0.90 | LMNA (0.97) | LMNACYP2D6DRD3HIF1ACYP3A4 | |
| Cinnarizine SCHEMBL3731525 | 0.90 | LMNA (0.97) | LMNACYP2D6DRD3HIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014186623-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE | BIOMED VALLEY DISCOVERIES (US) | 2014-11-20 | — | — | WO | claimed |
| EP-1919450-B1 | ANTIHISTAMINE- AND CORTICOSTEROID-CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | MEDA AB (SE) | 2014-06-11 | — | — | EP | claimed |
| US-20140065203-A1 | ANTIHISTAMINE- AND CORTICOSTEROID-CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | BIOLIPOX AB (SE) | 2014-03-06 | — | — | US | claimed |
| WO-2012101475-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ANTIHISTAMINIC DRUGS VIA A NOVEL CARBAMATE INTERMEDIATE | JUBILANT LIFE SCIENCES LIMITED (IN) | 2012-08-02 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090324699-A1 | Antihistamine-and corticosteroid-containing lipsome composition and its use for the manufacture of medicament for treating rhinitis and related disorders | MEDA AB (SE) | 2009-12-31 | — | — | US | claimed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | claimed |
| EP-1832287-B1 | The use of histamine receptor antagonists for the reduction of intracranial pressure | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-25 | — | — | EP | claimed |
| CN-101257891-A | Liposome composition comprising an antihistamine and a corticosteroid and its use for the preparation of a medicament for the treatment of rhinitis and related disorders | BIOLIPOX AB (SE) | 2008-09-03 | — | — | CN | claimed |
| EP-1919450-A1 | ANTIHISTAMINE- AND CORTICOSTEROID- CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | Biolipox AB (SE) | 2008-05-14 | — | — | EP | claimed |
| EP-1888033-A2 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS | Biolipox AB (SE) | 2008-02-20 | — | — | EP | claimed |
| EP-1832287-A2 | The use of anti-histaminics for acute reduction of elevated intracranial pressure | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-12 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007026151-A1 | ANTIHISTAMINE- AND CORTICOSTEROID- CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | BIOLIPOX AB (SE) | 2007-03-08 | — | — | WO | claimed |
| WO-2006131737-A2 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS | BIOLIPOX AB (SE) | 2006-12-14 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140065203-A1 | ANTIHISTAMINE- AND CORTICOSTEROID-CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | HRH1, HRH4, HRH3 | LMNA 3510/4885CYP2D6 1953/4885DRD3 955/4885 |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | LMNA 2837/4885CYP2D6 907/4885DRD3 2214/4885 |
| US-20090324699-A1 | Antihistamine-and corticosteroid-containing lipsome composition and its use for the manufacture of medicament for treating rhinitis and related disorders | LIPA, HRH1, HRH2 | LMNA 2555/4885CYP2D6 1221/4885DRD3 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.